SF3A1 and Ewing sarcoma: Conversely, in Ewing sarcoma [43] prostate cancer [47] ovarian cancer [48] and endometrial cancer [49] SOX6 displays oncogenic characteristics driven by distinct mechanisms such as constitutive activation through EWSR1-FLI1 fusion protein, regulation of non-coding enhancers (SF3A1 and CCDC157), and promotion of β-catenin signaling, respectively.